Conatus Pharmaceuticals Inc., of San Diego, reported 24-week interim data from a Phase II trial showing that CTS-1027 in combination with standard of care (SOC) peginterferon-alpha-2a and ribavirin resulted in sustained viral response at week 12 in 51 percent of null responder patients with hepatitis C virus. Complete data from the 24-week study are expected later this year.